VERTEX PHARMACEUTIC (VX1 HM) stock market data APIs
€374.7689
-2.8(-0.7%)
as of November 12, 2025
Try our APIs with
free plan!
VERTEX PHARMACEUTIC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for VX1.HM.
Prev. Close
374.7689
Open
371.9684
High
374.7689
Low
371.9684
52 wk Range
313.05-471.85
Market Cap
46 841 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get VERTEX PHARMACEUTIC data using free add-ons & libraries
Get VERTEX PHARMACEUTIC Fundamental Data
VERTEX PHARMACEUTIC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-03
- EPS/Forecast: 4.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
VERTEX PHARMACEUTIC News
New
The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress
Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA n...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
CRISPR Therapeutics AG -Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The Ne...
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment. Ma...
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerul...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
